AGP Executive Report
Last update: 30 minutes agoRegulatory Breakthrough: Pharming just cleared the EU for Joenja (leniolisib) for activated PI3K delta syndrome (APDS) in patients 12+—the first and only EU option—covering all 27 EU states plus Norway, Iceland and Liechtenstein, with the first launch expected in Germany in Q3 2026. Oncology Momentum: Merck’s KEYTRUDA plus Padcev combo for cisplatin-ineligible muscle-invasive bladder cancer also moved forward with a positive EU CHMP opinion, now awaiting an EU Commission decision expected in Q3 2026 for EU/EEA markets including Liechtenstein. Public Health Watch: Across Europe, STI rates hit record highs, with England flagged as the worst-hit by volume for syphilis, chlamydia and gonorrhoea—an issue that directly includes Liechtenstein in the broader regional picture. Diplomacy & Trade: India and the Nordics are pushing a “green” partnership agenda in Oslo, tying clean energy and innovation to wider economic cooperation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
